- Published
- Nov 17, 2026
- Respond by
- Dec 8, 2026, 14:00Closes in 18 days
- Latest amendment
- None
Procurement
- Procurement type
- Advance Contract Award Notice
- Procurement method
- Advance contract award notice
- Selection criteria
- Not applicable
- Category
- Goods
- Jurisdiction
- Federal
- Region of delivery
- Canada
- End user
- Public Health Agency of Canada (PHAC)
Not stated in the notice: expected contract period
See how this opportunity fits your company
Create a free account and describe your company. With the trial, CanPursue checks every opportunity against it and explains the fit.
Create free accountDescription
Advanced Contract Award Notice(ACAN) - Oblitoxaximab Injection
An ACAN is a public notice indicating to the supplier community that a department or agency intends to award a contract for goods, services or construction to a pre-identified supplier, thereby allowing other suppliers to signal their interest in bidding, by submitting a statement of capabilities. If no supplier submits a statement of capabilities that meets the requirements set out in the ACAN, on or before the closing date stated in the ACAN, the contracting officer may then proceed with the award to the pre identified supplier.
Purpose of this Advanced Contract Award Notice (ACAN):
Public Services and Procurement Canada proposes to negotiate a contract with Elusys Therapeutics, Inc on behalf of Public Health Agency of Canada (PHAC).
Requirement description:
Public Health Agency of Canada (PHAC) has a requirement for Oblitoxaximab injection, an antitoxin used to treat inhalation anthrax.
Documents
No attachments listed in the open data.
Contact
Ramenason, Anja (SPAC/PSPC)anja.ramenason@tpsgc-pwgsc.gc.ca
Source
Open official sourceVerify the notice and download the full solicitation on the official page.
- Source
- CanadaBuys
- Solicitation
- WS5994329939
- Reference number
- WS5994329939-Doc5994436969
- Observed
- Nov 19, 2026